Today: 7 February 2026
Subscribe
Browse Category

Earnings Reports News 13 January 2026

IBM stock drops 3% even after BofA lifts target — what to watch before earnings

IBM stock drops 3% even after BofA lifts target — what to watch before earnings

IBM shares fell about 3% Tuesday, underperforming a weaker U.S. market after Bank of America raised its price target but warned of a tougher 2026 setup. BofA expects $400 million in restructuring costs to weigh on fourth-quarter margins. Investors await IBM’s January 28 earnings for signals on software growth and cash flow. IBM’s $11 billion Confluent deal remains pending.
13 January 2026
··
Texas Instruments stock slips late in session as CPI hits tape and Jan. 27 earnings loom

Texas Instruments stock slips late in session as CPI hits tape and Jan. 27 earnings loom

Texas Instruments shares fell 0.5% to $188.12 Tuesday, lagging the broader chip sector as investors weighed new U.S. inflation data and awaited the company’s Jan. 27 earnings report. The iShares Semiconductor ETF rose 0.9%, while rivals Analog Devices and ON Semiconductor posted gains. U.S. consumer prices rose 0.3% in December, with core inflation up 2.6% year-over-year.
13 January 2026
·······
Verizon stock drops as FCC loosens phone unlocking rule and traders look to earnings next

Verizon stock drops as FCC loosens phone unlocking rule and traders look to earnings next

The FCC granted Verizon a waiver from its 60-day phone unlocking rule, allowing the carrier to follow broader industry standards. Verizon shares fell 2.4% to $38.89 Tuesday, underperforming peers after the decision. The company reported losing 784,703 devices to fraud in 2023. Verizon also amended a $30 million performance stock award for CEO Daniel H. Schulman.
13 January 2026
··
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer shares fell 0.6% to $25.12 in Tuesday afternoon trading after CEO Albert Bourla discussed plans to accelerate obesity drug trials at the J.P. Morgan Healthcare Conference. Bourla said Pfizer aims to launch 10 Phase 3 trials for its Metsera portfolio by 2026 but does not expect revenue growth before 2029. Investors await the Feb. 3 earnings report for updates on the obesity pipeline and guidance.
13 January 2026
···
ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow shares fell 3.3% to $137.95 Tuesday after Oppenheimer cut its price target to $200, citing sector concerns ahead of earnings. Goldman Sachs began coverage with a Buy rating and $205 target, while Citi maintained its Buy and placed the stock on a 30-day catalyst watch. The iShares Expanded Tech-Software ETF dropped 2%. Investors remain cautious after ServiceNow’s $7.75 billion Armis acquisition.
13 January 2026
··
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
13 January 2026
··
Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam shares fell 0.1% to $370.39 Tuesday afternoon after the company projected 2026 net product revenue between $4.9 billion and $5.3 billion. Preliminary 2025 sales were disclosed at $2.987 billion. Analysts remained mostly positive but flagged possible weakness for Amvuttra next quarter. The update came as Alnylam outlined its new five-year strategy at the J.P. Morgan Healthcare Conference.
13 January 2026
··
Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola shares rose 0.5% to $70.83 Tuesday after the company set Feb. 10 for its Q4 and full-year earnings release and investor call. CEO-elect Henrique Braun and CFO John Murphy will speak at the CAGNY conference in Orlando on Feb. 17. Coke expects a $1 billion impairment charge in Q4 tied to its Africa bottling sale. PepsiCo shares gained 1.4% while the S&P 500 ETF slipped 0.4%.
13 January 2026
··
Wells Fargo stock slides ahead of earnings as credit-card rate cap talk rattles banks

Wells Fargo stock slides ahead of earnings as credit-card rate cap talk rattles banks

Wells Fargo shares fell 1.6% to $93.44 Tuesday, ahead of its fourth-quarter earnings release set for 7 a.m. ET Wednesday. The drop followed President Trump’s proposal for a 10% cap on credit card interest rates, which hit bank stocks. Trading volume reached 11.4 million shares. Investors are watching credit costs and margins amid policy uncertainty and fresh inflation data.
13 January 2026
··
Western Digital stock ticks up as WDC sets Jan. 29 earnings, putting AI storage demand in focus

Western Digital stock ticks up as WDC sets Jan. 29 earnings, putting AI storage demand in focus

Western Digital shares rose 1.6% to $215.57 on Tuesday, ahead of its fiscal Q2 results set for Jan. 29 after the market closes. The stock has swung sharply in recent sessions, fueled by AI-driven demand for storage and recent bullish comments from Nvidia’s CEO. Analysts expect quarterly EPS of $1.92 and revenue near $2.91 billion. Seagate also gained, while Micron fell 2.3%.
13 January 2026
····
Lockheed Martin stock nears a fresh high after Jefferies target hike as earnings loom

Lockheed Martin stock nears a fresh high after Jefferies target hike as earnings loom

Lockheed Martin shares rose about 1% Tuesday, peaking at $564. Jefferies raised its price target to $540 but kept a Hold rating, citing possible weakness in 2026 guidance. Lockheed delivered its 350th MH-60R helicopter to the U.S. Navy and hosted Secretary of War Pete Hegseth at its F-35 plant. Investors await fourth-quarter results on Jan. 29 for details on 2026 margins and production.
13 January 2026
···
Roblox stock jumps as BMO flags a breakout game and Feb. 5 earnings loom (RBLX)

Roblox stock jumps as BMO flags a breakout game and Feb. 5 earnings loom (RBLX)

Roblox shares rose 8% to $83.09 in midday New York trading Tuesday, after touching $83.98 and trading as low as $76.05. The company will report fourth-quarter and full-year 2025 results after the bell on Feb. 5. BMO reiterated an Outperform rating, citing strong early performance of a new game. New York’s governor is pushing for stricter online gaming rules affecting Roblox, The Verge reported.
13 January 2026
····
Why Goldman Sachs stock is down today: Apple Card handoff and CPI sharpen focus on Jan. 15 earnings

Why Goldman Sachs stock is down today: Apple Card handoff and CPI sharpen focus on Jan. 15 earnings

Goldman Sachs shares fell 0.8% to $942.01 in midday New York trading Tuesday as big banks began reporting earnings. JPMorgan booked a $2.2 billion provision tied to taking over the Apple Card from Goldman. U.S. core inflation rose 0.2% in December, steadying bets on Federal Reserve rate cuts. Treasury yields slipped after the inflation data.
13 January 2026
··
Scorpio Tankers stock jumps nearly 9% on net-cash update as investors eye a February catalyst

Scorpio Tankers stock jumps nearly 9% on net-cash update as investors eye a February catalyst

Scorpio Tankers shares surged nearly 9% to $59.85 by midday Tuesday after the company reported a net cash position of $164.7 million, outstripping its debt. A U.S. filing showed Scorpio agreed to sell the LR2 tanker STI Kingsway for $57.5 million, with closing expected in early 2026. Investors are watching the timing of vessel sales and related cash flows. Peers Frontline and International Seaways rose about 3%.
13 January 2026
··
Option Care Health (OPCH) stock jumps nearly 10% on early Q4 results, 2026 outlook and a bigger buyback

Option Care Health (OPCH) stock jumps nearly 10% on early Q4 results, 2026 outlook and a bigger buyback

Option Care Health shares rose nearly 10% to $35.16 Tuesday after the company released preliminary Q4 results and doubled its share buyback authorization to $1.0 billion. The company projects Q4 net revenue of $1.46–$1.47 billion and adjusted EPS of $0.46–$0.49. A Citizens analyst raised the price target to $38, citing easing Stelara-related risk after 2026.
13 January 2026
··
1 … 91 92 93 94 95 … 202

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
New York, Feb 7, 2026, 09:39 EST — Market closed. Apple Inc (AAPL.O) shares ended Friday up 0.8% at $278.12 after swinging between $276.92 and $280.90, before dipping 0.3% in after-hours trading. U.S. markets are shut on Saturday, but the stock goes into Monday with a familiar question back on the tape: will Apple raise iPhone prices, or eat higher costs. (Investing.com data) The immediate pressure point is memory. A tightening supply of DRAM — the memory chips that help phones run power-hungry apps smoothly — is pushing up component costs just as investors are re-pricing the economics of the
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
Go toTop